Sept-ah kum 2 chunglam tan Covaxin lak theih dawn : Delhi AIIMS Chief
India rama Covid-19 vaccine siamchhuah hmasak ber, Covaxin chu naupang hman theih turin September hmaa peih hman tum a nih thu Delhi AIIMS chief Dr. Randeep Guleria chuan a sawi.
Guleria chuan, "Covaxin naupang tana tihchhuah tur hi Phase 2/3 trial zawh a ni tawh a, September thlaah hman theihin a awm dawn a, hemi thla vek hian a pawmpuina a chhuah nghal kan beisei a ni", a ti.
Covaxin bakah hian Pfizer-BioNTech vaccine chu India-a hman tura pawm a nih chuan, naupang tan vaccine hi hman theih a ni dawn bawk tih a sawi.
June 7 khan Delhi AIIMS hian naupang kum 2 - 17 inkar tan vaccine clinical trial an kalpui ṭan tawh a ni. May thla khan Drugs Controller General of India (DCGI) chuan Bharat Biotech hnenah hian naupang kum 2 chin thleng hnenah Covaxin phase 2-3 trial neihpui a lo phalsak tawh a ni.
Dr Guleria hian India rama mipui pungkhawmna siam te, sorkarin hri laka invenna tur kaihhruaina a siamte bawhchhiat a nih chhoh zel chuan Covid-19 thawh thumna chu kar ruk - kar riat chhungin a lo thleng leh thei a nih tih sawi. "Covid-appropriate behaviour zawm a nih loh chuan hri leng thawh thumna hi kar ruk - kar riat inkara lo thleng thei a ni. Mi tam zawk hnena vaccine kan pekchhuah hma chu chhumlo chatloa hri dona kawnga hna kan thawh chhunzawm a ngai a ni," a ti.
Subject Expert Committee (SEC) chuan Thawhlehni khan Covaxin phase 3 trial data chu an pawm a, he data-a hian Covaxin hian hri lakah 77.8% in a veng thei tih tarlan a ni. DCGI hnenah data hi ennawn turin thawn a ni ve leh ang.